# A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

> **NCT01094483** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (estimated)

## Conditions studied

- Platelet Inhibition

## Interventions

- **DRUG:** PN400
- **DRUG:** ASA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01094483
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2010-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01094483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01094483, "A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01094483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*